Wachtwoord vergeten?

Aandeel Pharming Group AEX:PHARM, NL0010391025

  • 1,157 25 jan 2021 17:35
  • -0,029 (-2,41%) Dagrange 1,156 - 1,198
  • 8.675.468 Gem. (3M) 12M

Pharming juni 2020

7.103 Posts
Pagina: «« 1 ... 285 286 287 288 289 ... 356 »» | Laatste | Omlaag ↓
  1. forum rang 6 zjeeraar 24 juni 2020 23:14
    De flinke stijging van het aantal nieuwe Corona besmettingen in verschillende Amerikaanse staten maakte beleggers enigszins nerveus, ook gelet op mogelijke lockdowns.

    Wie nu nog eens de opmerking gaat maken dat Pharming te laat komt met zijn Covid-19 Basel onderzoek moet maar gaan emigreren naar de States.......
  2. [verwijderd] 24 juni 2020 23:53

    Eric de Rus schreef op 24 juni 2020 22:41:


    Pech?? Heeft niks met pech te maken hoor.

    Pharming bakt er gewoon niks van. Ja, bla bla chocoladevla en zwarte cijfers met puntjes van onnozele particulieren ;))

    Pharming is niks meer of minder dan een kraslot. De uitgever van de krasloten wint altijd.

    Daarom is Pharming zo'n mooi aandeel om short te gaan. Genoeg particulieren die dollartekens in hun ogen hebben en Pharming kopen.

    200.000.000 omzet. Ja ze bakken er niks van.
    Bijna schuldloos. Ja ze bakken er niks van.
    Komen nog veel mooie dingen aan.
  3. jakhals 25 juni 2020 08:02
    Coulter Partners secures Supervisory Board Directors for Pharming Group

    Published: 24 Jun 2020 By Nola Cadman

    Coulter Partners secures Supervisory Board Directors for Pharming Group Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors. Pharming Group N.V. is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Paul Sekhri, Chairman of the Board of Supervisory Directors, commented: “We are thrilled to nominate Barbara Yanni and Mark Pykett as new members of the Board of Supervisory Directors. Their extensive experience and strong track record in pharmaceuticals and biotechnology in the US complements the existing expertise of our Board. Accordingly, they will further strengthen the Board’s ability to effectively oversee Pharming’s fast-growing global business activities, especially those in the increasingly important US market and I thank the team at Coulter Partners for their professional support in achieving these key nominations.” Sijmen de Vries, Chief Executive Officer, added:“I welcome Barbara Yanni and Mark Pykett to Pharming. I look forward to
    working closely with them both, as we continue to implement our growth
    strategy from a strong financial position with additional cash resources to
    invest in the Company’s long-term prospects.”
    Barbara Yanni
    Barbara Yanni has over thirty-five years of experience in pharmaceuticals and
    biotechnology. She currently serves as an independent director of three
    public clinical-stage biopharmaceutical companies, including Trevena
    (NASDAQ: TRVN), Vaccinex (NASDAQ: VCNX) and Akcea (NASDAQ:
    AKCA). In the past, Barbara served as a board member of Abionyx (Paris:
    ABNX) and Symic Bio, a private biotech company.
    Barbara retired from Merck & Co., Inc. in 2014 after 12 years as Vice
    President and Chief Licensing Officer. At Merck, Barbara and her licensing
    team successfully structured and negotiated agreements to acquire rights to
    over 150 compounds, programs and technologies to enhance the pipeline. In
    addition, Barbara significantly increased Merck's visibility as a preferred
    partner. Barbara began her Merck career as a tax lawyer and then
    transitioned to finance, first as Director of Benefits Financing and
    subsequently as Senior Director of Financial Evaluations and Analysis where
    she evaluated the financial aspects of acquisitions, joint ventures, licenses
    and other transactions.
    Barbara has a JD from Stanford Law School and an AB from Wellesley
    College where she studied Physics and Latin. She also holds a Masters of
    Law in Taxation from New York University
    Mark Pykett
    Mark Pykett is Chief Scientific Officer of PTC Therapeutics (NASDAQ: PTCT).
    Before joining PTC in 2018, Mark held a number of executive positions,
    including president and Chief Executive Officer (CEO) of Agilis
    Biotherapeutics, CEO of Navidea Biopharmaceuticals (NYSE MKT: NAVB),
    and president and CEO of Alseres Pharmaceuticals (ALSE.PQ), among
    others. Mark also served as a director of several public and private
    companies, as well as the not-for-profit organisation, HealthBuilders, which
    develops health infrastructure in central Africa.Mark received his B.A. from Amherst College, a V.M.D. and Ph.D. from the
    University of Pennsylvania, and an M.B.A. from Northeastern University, and
    completed postdoctoral fellowships at the University of Pennsylvania and
    Harvard University.
    About Pharming Group N.V.
    Pharming is a specialty pharmaceutical company developing innovative
    products for the safe, effective treatment of rare diseases and unmet medical
    needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a
    recombinant human C1 esterase inhibitor approved for the treatment of acute
    Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel
    and South Korea. The product is available on a named-patient basis in other
    territories where it has not yet obtained marketing authorisation.
    Additional information is available on the Pharming website:
    About Coulter Partners
    Coulter Partners is a board and senior level executive search boutique
    focussed exclusively on global Life Sciences. From our offices in the UK,
    Europe, North America and Asia-Pacific, we work together across boundaries
    and disciplines to build outstanding leadership teams for our clients in the
    pharmaceuticals, biotechnology, medical devices, health tech, diagnostics,
    CRO and services sectors. Our industry leading reputation is founded on
    deep sector knowledge and innovative thinking. Our strategy is built on a
    unique team culture and true global reach. Our goal is to bring you the
    world’s best talent.
  4. [verwijderd] 25 juni 2020 08:55

    Dekkie schreef op 24 juni 2020 21:18:

    Gaan we oude koeien uit de sloot halen.

    Klopt, en deze zal ik nog geregeld blijven delen. Het zijn veelal zelfbenoemde 'kenners' die nu bijna twee jaar na dato nog steeds mijlenver van de realiteit af liggen met hun euforistische koersdoelen die binnen een paar maanden zeker gehaald zouden worden.
    Beide beentjes aan de grond houden is het devies.
7.103 Posts
Pagina: «« 1 ... 285 286 287 288 289 ... 356 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Pharming Group Meer »

Koers 1,157   Verschil -0,03 (-2,41%)
Laag 1,156   Volume 8.675.468
Hoog 1,198   Gem. Volume 11.998.783
25 jan 2021 17:35
label premium

Omzetherstel bij Pharming

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Gerelateerde Video's

  1. video thumbnail

    Outlook Pharming

    7 juni 2018 16:58 - Vimeo

  2. video thumbnail

    Pharming: Groeiperspectieven

    13 maart 2018 22:16 - Vimeo

  3. video thumbnail

    Pharming kan verder omhoog

    27 oktober 2017 17:23 - Vimeo

  4. video thumbnail

    Arend Jan Kamp over Pharming

    26 oktober 2017 13:24 - Vimeo

Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare